Angeles Secord

Overview:

My primary research interest has focused on angiogenesis, molecular signatures, clinical trial development, and ovarian cancer. My fundamental goal is to develop a strong translational research program at Duke University in the Gynecologic Oncology Division where knowledge we glean from our basic science research can be incorporated into our clinical trial program. Specifically on anti-angiogenic therapy and molecular tumor signatures to direct therapy in patients with ovarian cancer to determine if a strategy that incorporates both clinical and genomic information can improve clinical outcome, minimize unnecessary toxicity, and impact positively on quality of life.
In addition I am interested in robotic-assisted laparoscopic surgery for women with endometrial, ovarian, and cervical cancers as well as for benign gynecologic conditions.

Positions:

Professor of Obstetrics and Gynecology

Obstetrics and Gynecology, Gynecologic Oncology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.D. 1994

University of Washington

Resident, Obstetrics & Gynecology

Duke University

Grants:

Predictive value of the IL6 pathway to direct anti-angiogenic therapy in advanced ovarian cancer

Administered By
Obstetrics and Gynecology, Gynecologic Oncology
Awarded By
American Association of Obstetricians and Gynecologists Foundation
Role
Principal Investigator
Start Date
End Date

Biomarker Discovery to Direct Bevacizumab Therapy in Ovarian Cancer - Blood-based Angiome Profiling

Administered By
Obstetrics and Gynecology, Gynecologic Oncology
Awarded By
National Institutes of Health
Role
Principal Investigator
Start Date
End Date

TESARO LUNG AND ENDOMETRIAL CANCER PRACTICUM

Administered By
Medicine, Medical Oncology
Awarded By
TESARO
Role
Co-Principal Investigator
Start Date
End Date

SGNTV-002: Open Label Phase 2 Study of Tisotumab Vedotin for Patients with Platinum-Resistant Ovarian Cancer with a Safety Run-in of a Dose-Dense Regimen

Administered By
Duke Cancer Institute
Awarded By
Seattle Genetics, Inc
Role
Principal Investigator
Start Date
End Date

A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab Versus Treatment of Physician¿s Choice in Participants with Adva

Administered By
Duke Cancer Institute
Awarded By
Merck Sharp & Dohme
Role
Principal Investigator
Start Date
End Date

Publications:

Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.

Inhibitors of poly(ADP-ribose) polymerase (PARP) and angiogenesis have demonstrated single-agent activity in women with advanced ovarian cancer. Recent studies have aimed to establish whether combination therapy can augment the response seen with PARP inhibitors or antiangiogenic agents alone. This review provides an overview of PARP inhibitors and antiangiogenics as monotherapy in women with advanced ovarian cancer, explores potential mechanisms of action of PARP inhibitor and antiangiogenic combination treatments, reviews efficacy and safety data from trials evaluating this combination, and outlines ongoing and future trials evaluating this combination, discussing these in the context of the current and future treatment landscape for women with advanced ovarian cancer. Sentinel studies evaluating PARP inhibitor (n = 8), antiangiogenic (n = 4), and combination (n = 7) therapy were identified in women with newly diagnosed (n = 7) and recurrent (n = 12) ovarian cancer. PARP inhibitors included olaparib (n = 9), niraparib (n = 4), rucaparib (n = 1), and veliparib (n = 1). Antiangiogenic agents included bevacizumab (n = 7) and cediranib (n = 4). PARP inhibitors combined with antiangiogenics demonstrated efficacy based on objective response rates and progression-free survival (PFS) in the relapsed disease setting. Maintenance therapy with the PARP inhibitor, olaparib, plus antiangiogenic therapy offered a significant PFS benefit versus the antiangiogenic alone in women with newly diagnosed advanced ovarian cancer who tested positive for homologous recombination deficiency. Combination therapy was tolerated, with no new safety signals reported compared with monotherapy trials. PARP inhibitors and antiangiogenics have changed the landscape of ovarian cancer treatment. The PARP inhibitor plus antiangiogenic combination is a novel treatment option that appears promising in the first-line advanced and recurrent ovarian cancer settings, although the role of this combination in recurrent disease requires further elucidation. Defining which patients are candidates for monotherapy or combination therapy is critical, taking into consideration safety profiles of therapies alone or in combination, and how these treatments should be sequenced in clinical practice.
Authors
Alvarez Secord, A; O'Malley, DM; Sood, AK; Westin, SN; Liu, JF
MLA Citation
Alvarez Secord, Angeles, et al. “Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.Gynecol Oncol, vol. 162, no. 2, Aug. 2021, pp. 482–95. Pubmed, doi:10.1016/j.ygyno.2021.05.018.
URI
https://scholars.duke.edu/individual/pub1493384
PMID
34090705
Source
pubmed
Published In
Gynecol Oncol
Volume
162
Published Date
Start Page
482
End Page
495
DOI
10.1016/j.ygyno.2021.05.018

A multi-institutional study of minimally invasive surgery compared to laparotomy for interval debulking after neoadjuvant chemotherapy in women with advanced ovarian cancer

Authors
Brown, J; Barr, A; Zhang, Y; Davidson, B; Secord, AA; Drury, L; Crane, E; Tait, D; Naumann, RW; McNally, L
URI
https://scholars.duke.edu/individual/pub1496056
Source
wos-lite
Published In
Gynecologic Oncology
Volume
162
Published Date
Start Page
S20
End Page
S20

Obesity is associated with altered angiogenic gene expression in endometrioid endometrial cancer

Authors
Cobb, LP; Siamakpour-Reihani, S; Zhang, D; Owzar, K; Berchuck, A; Bae-Jump, VL; Secord, AA
MLA Citation
Cobb, L. P., et al. “Obesity is associated with altered angiogenic gene expression in endometrioid endometrial cancer.” Gynecologic Oncology, vol. 149, Elsevier BV, 2018, pp. 177–78. Crossref, doi:10.1016/j.ygyno.2018.04.404.
URI
https://scholars.duke.edu/individual/pub1467279
Source
crossref
Published In
Gynecologic Oncology
Volume
149
Published Date
Start Page
177
End Page
178
DOI
10.1016/j.ygyno.2018.04.404

AdoRN Trial: Atezolizumab in combination with neoadjuvant chemotherapy and interval cytoreductive surgery for patients with newly-diagnosed advanced-stage epithelial ovarian cancer

Authors
Gaillard, S; Duska, L; Broadwater, G; McNally, L; Lee, P; Davidson, B; Previs, R; Moss, H; Berchuck, A; Nixon, A; Yi, J; Bookman, M; Secord, AA
URI
https://scholars.duke.edu/individual/pub1496274
Source
wos-lite
Published In
Gynecologic Oncology
Volume
162
Published Date
Start Page
S61
End Page
S61

Baseline platelet count and body weight as predictors of early dose modification in the quadra trial of niraparib monotherapy for the treatment of heavily pretreated (≥4th line), advanced, recurrent high-grade serous ovarian cancer

Authors
Matulonis, UA; Monk, BJ; Secord, AA; Geller, MA; Miller, DS; Cloven, NG; Fleming, GF; Hendrickson, AEW; Azodi, M; DiSilvestro, PA; Oza, AM; Cristea, M; Berek, JS; Chan, JK; Li, Y; Luptakova, K; Hazard, SJ; Moore, KN
URI
https://scholars.duke.edu/individual/pub1467414
Source
crossref
Published In
Gynecologic Oncology
Volume
154
Published Date
Start Page
3
End Page
3
DOI
10.1016/j.ygyno.2019.04.017